A possible antienuretic effect of reboxetine in children and adolescents with attention deficit/hyperactivity disorder: case series.
Reboxetine is a selective norepinephrine reuptake inhibitor. To evaluate the antienuretic effect of reboxetine in children with attention deficit and mood disorders. Six children aged 12-15 years with primary nocturnal enuresis and with attention deficit/hyperactivity disorder with or without other comorbid disorders were treated with reboxetine (4-8 mg/day). Monitoring of enuretic frequency was recorded at baseline and once a week for 6 weeks. A statistically significant decrease in bedwetting was noted along the assessment points (p < 0.001), with the maximal change noted in the first week of treatment (p = 0.004). Reboxetine was well tolerated with minimal and transient side effects. reboxetine may possess an antienuretic effect in some children with the attention deficit/hyperactivity disorder.